Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Revlimid in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Hodgkin's Lymphoma (NHL)

NCT00695786 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT00695786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00695786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Revlimid in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Hodgkin's Lymphoma (NHL)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
June 10, 2008
Completion date
July 11, 2020
Enrollment
156 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage iii grade 1 follicular lymphoma, ann arbor stage iii grade 2 follicular lymphoma, ann arbor stage iii indolent adult non-hodgkin lymphoma, ann arbor stage iii marginal zone lymphoma, ann arbor stage iii small lymphocytic lymphoma, ann arbor stage iv grade 1 follicular lymphoma, ann arbor stage iv grade 2 follicular lymphoma, ann arbor stage iv indolent adult non-hodgkin lymphoma, ann arbor stage iv marginal zone lymphoma, ann arbor stage iv small lymphocytic lymphoma